Second Half Financial Partners LLC Buys New Position in Johnson & Johnson (NYSE:JNJ)

Second Half Financial Partners LLC purchased a new stake in Johnson & Johnson (NYSE:JNJ) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 21,310 shares of the company’s stock, valued at approximately $3,454,000. Johnson & Johnson makes up 1.8% of Second Half Financial Partners LLC’s portfolio, making the stock its 13th largest holding.

A number of other hedge funds have also added to or reduced their stakes in JNJ. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $72,049,000. Vance Wealth Inc. boosted its position in shares of Johnson & Johnson by 1.2% during the third quarter. Vance Wealth Inc. now owns 19,188 shares of the company’s stock valued at $3,110,000 after purchasing an additional 227 shares in the last quarter. Beddow Capital Management Inc. grew its stake in Johnson & Johnson by 2.6% in the third quarter. Beddow Capital Management Inc. now owns 51,830 shares of the company’s stock worth $8,400,000 after purchasing an additional 1,290 shares during the period. First City Capital Management Inc. raised its holdings in Johnson & Johnson by 8.5% in the third quarter. First City Capital Management Inc. now owns 11,003 shares of the company’s stock worth $1,783,000 after purchasing an additional 858 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 13.5% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 19,775 shares of the company’s stock valued at $3,205,000 after buying an additional 2,350 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. Royal Bank of Canada lifted their price target on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Wells Fargo & Company upped their price target on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Guggenheim increased their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.94.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $152.97 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company has a 50 day moving average price of $160.83 and a 200-day moving average price of $156.19. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The firm has a market capitalization of $368.29 billion, a PE ratio of 22.14, a P/E/G ratio of 2.74 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.66 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.24%. Johnson & Johnson’s payout ratio is 71.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.